Seattle and Seoul, April 11, 2016 - PATH and Standard Diagnostics (SD)/Alere announced today the commercial availability of two rapid diagnostic tools for onchocerciasis and lymphatic filariasis.

Alere, Inc. and its San Diego subsidiary, agreed to pay $38.75 million to resolve False Claims Act charges for billing the Medicare program for defective rapid point-of-care testing devices.

Inc. The Alere Filariasis test strips were donated by the manufacturer and BinaxNOW Filariasis card tests were financed by the research project. The paper reports the results of an independent ...

Inc. The Alere Filariasis test strips were donated by the manufacturer and BinaxNOW Filariasis card tests were financed by the research project. The paper reports the results of an independent ...

Federal investigators are seeking information about government-billing practices at Alere Inc., adding to a litany of woes at the diagnostic-testing company as it seeks to complete a deal to sell ...